Verve Therapeutics (VERV) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free VERV Stock Alerts $6.01 -0.35 (-5.50%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHC Wainwright Reaffirms "Buy" Rating for Verve Therapeutics (NASDAQ:VERV)americanbankingnews.com - May 12 at 2:26 AMVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimatesfinance.yahoo.com - May 11 at 9:26 AMBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financialsmarkets.businessinsider.com - May 10 at 6:25 PMAnalysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Weekfinance.yahoo.com - May 10 at 10:17 AMVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3% on Earnings Beatamericanbankingnews.com - May 10 at 2:04 AMRBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)markets.businessinsider.com - May 9 at 7:16 PMBuy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potentialmarkets.businessinsider.com - May 9 at 7:16 PMVerve Therapeutics (NASDAQ:VERV) Rating Reiterated by HC Wainwrightmarketbeat.com - May 9 at 4:46 PMVerve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Expectations By $0.11 EPSmarketbeat.com - May 9 at 2:03 PMVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3% Following Strong Earningsmarketbeat.com - May 9 at 10:36 AMVerve Therapeutics First Quarter 2024 Earnings: Beats Expectationsfinance.yahoo.com - May 9 at 9:18 AMBuy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipelinemarkets.businessinsider.com - May 8 at 11:17 PMVerve Therapeutics GAAP EPS of -$0.59 beats by $0.12, revenue of $5.7M beats by $3.45Mmsn.com - May 8 at 6:16 PMVERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com - May 8 at 3:17 PMVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Resultsfinance.yahoo.com - May 8 at 8:52 AMVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102finance.yahoo.com - May 7 at 9:47 AMVerve Therapeutics (NASDAQ:VERV) Trading 7.8% Higher americanbankingnews.com - May 5 at 4:34 AMVerve Therapeutics (NASDAQ:VERV) Trading Up 7.8%marketbeat.com - May 3 at 9:33 PMVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 3 at 4:01 PMVerve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $5.93americanbankingnews.com - May 3 at 5:20 AMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $5.93marketbeat.com - May 1 at 12:28 PMVerve Therapeutics (NASDAQ:VERV) Hits New 52-Week Low at $6.05marketbeat.com - April 25 at 3:44 PMSumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 21 at 5:16 AMFederated Hermes Inc. Purchases 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 20 at 7:16 AMGV’s Newest Life Sciences General Partner Pursues Precision Treatmentswsj.com - April 18 at 9:55 AMVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77msn.com - April 18 at 12:03 AMVerve Therapeutics (NASDAQ:VERV) Stock Price Down 2.9%marketbeat.com - April 17 at 12:20 PMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $7.26marketbeat.com - April 15 at 2:48 PMTop 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarterbenzinga.com - April 11 at 8:46 AMBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recoverymarkets.businessinsider.com - April 9 at 8:55 AMA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest Twistmsn.com - April 9 at 8:55 AMVerve Therapeutics (NASDAQ:VERV) Coverage Initiated at HC Wainwrightmarketbeat.com - April 8 at 8:20 AMVerve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Raised by Vanguard Group Inc.marketbeat.com - April 8 at 4:08 AMAfter a Serious Setback, Is Verve Therapeutics a Buy?fool.com - April 6 at 9:50 AMVerve Therapeutics (NASDAQ:VERV) Stock Price Up 4.8%marketbeat.com - April 4 at 2:24 PMJoan Nickerson Sells 1,514 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) Stockinsidertrades.com - April 4 at 7:09 AMGene Editing Experiment Halted as Patient Gets Weird Side Effectsmsn.com - April 3 at 10:43 PMVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 1,514 Sharesmarketbeat.com - April 3 at 6:58 PMVerve Therapeutics: An Update On Human CRISPRseekingalpha.com - April 3 at 2:15 PMVerve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pauseseekingalpha.com - April 3 at 11:57 AMVerve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effectmsn.com - April 2 at 9:34 PMBuy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 Programmarkets.businessinsider.com - April 2 at 9:34 PMVerve’s stock tumbles as biotech pauses gene editing trial over safety concernsbizjournals.com - April 2 at 4:34 PMVerve Therapeutics Pauses Enrollment in Trial of Gene Editing Medicine After Serious Adverse Eventmarketwatch.com - April 2 at 11:33 AMVerve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock Fallsmarkets.businessinsider.com - April 2 at 11:33 AMVerve drops after pausing enrollments in trial for lead assetmsn.com - April 2 at 11:33 AMVerve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setbackmsn.com - April 2 at 11:33 AMVerve Falls as Gene-Editing Trial Paused on Safety Issuesfinance.yahoo.com - April 2 at 11:33 AMVerve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effectsfinance.yahoo.com - April 2 at 11:33 AMVerve Therapeutics (NASDAQ:VERV) Shares Gap Down to $12.79marketbeat.com - April 2 at 11:18 AM Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide VERV Media Mentions By Week VERV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.580.58▲Average Medical News Sentiment VERV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼194▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Altimmune News Today Larimar Therapeutics News Today KalVista Pharmaceuticals News Today Travere Therapeutics News Today Oculis News Today Shattuck Labs News Today COMPASS Pathways News Today Adlai Nortye News Today Arbutus Biopharma News Today Astria Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking: One AI startup's revenue could surge 4,735%Manward PressElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin Analytics[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
